ClinicalTrials.gg
CompletedNCT05708794Updated Feb 12, 2024

Adjust-Unlikely PE

An observational study in Pulmonary Embolism (Diagnosis), sponsored by Dr. Kerstin de Wit. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-12.

Sponsored by Dr. Kerstin de Wit · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 74 studies in Pulmonary Embolism with a site in Canada — 7 open to participants now, 9 under way, 3 of them phase 3. Pulmonary Embolism · Canada.

Enrollment
15th of 20
200 · median 612
Started
2023
with 3 others
Observational
20 of 74
1 open now
Registered
68th of 74
by date
Lead sponsor
2 of 74
Dr. Kerstin de Wit

Among the 74 studies in Pulmonary Embolism with a site in Canada, this one is the 15th largest by enrollment of the 20 observational ones that give a count, is one of 4 that started in 2023, is one of 20 observational ones, and was the 68th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

7 of the 74 studies in Pulmonary Embolism with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Pulmonary Embolism with a site in Canada, or all of them as a file.
02

Study summary

The aim of this pilot study is to assess the feasibility of a larger study to determine the Adjust-Unlikely algorithm safety and efficiency for diagnosing PE.

The pilot study objectives are to:

  1. Determine study recruitment rate, per site, per month
  2. Determine study 90-day loss to follow up rate
  3. Estimate of the proportion of enrolled patients who test negative for PE at initial assessment using the Adjust-Unlikely rule
  4. Estimate of the Adjust-Unlikely algorithm efficiency
  5. Compare excluded and missed-eligible patients to study participants: age, sex and prevalence of PE diagnoses at initial testing.

The pilot study hypothesis is that the investigators can recruit at least 20 patients per month and successfully follow at least 90% of patients for 90 days.

03

Conditions studied

  • Pulmonary Embolism (Diagnosis)

Keywords

  • emergency medicine
  • standardization of practice
  • diagnostics evaluation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients presenting to emergency departments and urgent care centres with symptoms of PE.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Emergency physician decides to test for PE

Exclusion criteria

Exclusion Criteria:

  • Tested for PE without using the Adjust-Unlikely algorithm
  • D-dimer level is known before Adjust-Unlikely assessment
  • A new indication for anticoagulation on emergency department assessment (other than pulmonary embolism) in a patient not previously prescribed an anticoagulant
  • Declines participation
  • Is inaccessible for follow-up
  • Has previously participated in this study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The proportion of patients who have PE excluded by the Adjust-Unlikely algorithm and who are subsequently diagnosed with either PE or lower limb DVT.

    Time frame: 90 days following index presentation

07

Study locations

1 site
  • Kingston Health Sciences Centre
    Kingston, Ontario K7L 2V7, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Sep 2023, 4 months.

Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's 4 months is below that.

Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Feb 1, 2023
StartActual
Apr 23, 2023
Primary completionActual
Sep 8, 2023
CompletionActual
Dec 22, 2023
Last update
Feb 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05708794
Lead sponsor
Dr. Kerstin de Wit
Collaborators
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Responsible party
Dr. Kerstin de Wit (Dr. Kerstin de Wit, Associate Professor, Department of Emergency Medicine, Queen's University, Kingston Health Sciences Centre) — Sponsor-investigator
First posted
Feb 1, 2023
Start date
Apr 23, 2023
Primary completion
Sep 8, 2023
Completion
Dec 22, 2023
Last update
Feb 12, 2024

Study contacts

Kerstin de Wit
principal investigator · Kingston Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion